Aandeel IMNM IMMUNOME, INC.
Toevoegen aan een lijst
Om deze functie te gebruiken moet u een klant of lid zijn.
InloggenRegistreren

Andere talen Immunome, Inc.

Aandelen

IMNM

US45257U1088

Geschatte realtime Cboe BZX
Andere beurzen
 19:06:58 14-05-2024 		Variatie 5 dagen Verschil t.o.v. 1 jan (%)
14,91 USD -4,48% Intraday-grafiek van Immunome, Inc. -2,61% +39,53%
02/05 Immunome, Inc. Benoemt Kinney Horn tot Chief Business Officer CI
30/04 IMMUNOME, INC. : JPMorgan Chase nog altijd een koopadvies ZM

Andere talen

Zoeken op
Resultaten bekijken
Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!
Gratis inschrijven
Immunome Reports First Quarter 2024 Financial Results and Provides Business Update
Certain Common Stock of Immunome, Inc. are subject to a Lock-Up Agreement Ending on 14-MAY-2024.
Certain Warrants of Immunome, Inc. are subject to a Lock-Up Agreement Ending on 14-MAY-2024.
Certain Stock Options of Immunome, Inc. are subject to a Lock-Up Agreement Ending on 14-MAY-2024.
Immunome to Present at 2024 Bank of America Healthcare Conference
Immunome Appoints Kinney Horn as Chief Business Officer
Immunome, Inc. Appoints Kinney Horn as Chief Business Officer
Immunome Appoints Sandra M. Swain to Board of Directors
Immunome, Inc. Appoints Sandra M. Swain to Board of Directors
Immunome to Present Preclinical Data for IM-3050, Its Lead Radioligand Therapy Candidate, at 2024 American Association for Cancer Research Annual Meeting
Immunome to Present Preclinical Data for IM-3050, Its Lead Radioligand Therapy Candidate, at 2024 American Association for Cancer Research (AACR) Annual Meeting
Immunome, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Immunome Reports Full Year 2023 Financial Results and Provides Update on Recently Acquired Assets
Immunome Completes Acquisition of AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala
Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome
Immunome, Inc. completed the acquisition of Assets from Ayala Pharmaceuticals, Inc..
Immunome to Participate in the Leerink Partners Global Biopharma Conference
Immunome to Participate in the TD Cowen 44th Annual Healthcare Conference
Immunome to Participate in the TD Cowen 44th Annual Healthcare Conference
Immunome Recognizes Ayala Pharmaceuticals Announced Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors
Geen resultaten voor deze zoekopdracht
Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Filters

Zoeken op

Datum van publicatie

Sinds de

Tot

  1. Beurs
  2. Aandelen
  3. Koers IMNM
  4. Nieuws Immunome, Inc.
  5. Andere talen